- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Imricor Medical Systems Highlights H2 Earnings
Company frames year as 'proven to ready' with regulatory milestones, expanding clinical activity, and commercial infrastructure build.
Published on Feb. 26, 2026
Got story updates? Submit your updates here. ›
Imricor Medical Systems (ASX:IMR) used its full-year FY2025 results call to highlight progress across regulatory, clinical, and commercial fronts as it aims to move cardiac ablation procedures from traditional X-ray cath labs to MRI environments. Key milestones included the first-in-human ischemic ventricular tachycardia (VT) ablation under real-time MRI guidance, FDA clearance for its NorthStar and Vision-MR diagnostic catheter products, and expansion of its VISABL-AFL clinical trial to additional U.S. sites.
Why it matters
Imricor's focus on MRI-guided cardiac ablation represents an innovative approach that could improve outcomes and efficiency compared to traditional X-ray-guided procedures, which the company says have 'very disappointing' results for ventricular tachycardia (VT) in particular. The regulatory and clinical progress, as well as the commercial infrastructure build, position the company to potentially drive broader adoption of its technology.
The details
On the regulatory and clinical front, Imricor highlighted the first-in-human ischemic VT ablation under real-time MRI guidance, FDA clearance for its NorthStar and Vision-MR diagnostic catheter products, and expansion of its VISABL-AFL trial to additional U.S. sites. Commercially, the company completed integration and testing of NorthStar on the Philips MRI platform, hired a European sales team, and saw its European customer pipeline grow from 7 to 40 by year-end. Financially, the company reported a net loss of $25.3 million, a 15% improvement from the prior year, and ended the year with $40.8 million in cash and marketable securities.
- Imricor completed a large human factors study across its products in FY2025 to support FDA approval efforts.
- NorthStar and the Vision-MR diagnostic catheter were submitted for 510(k) clearance and cleared by the FDA in January.
- Imricor expanded its VISABL-AFL trial, adding the University of Virginia, Virginia Commonwealth University, and Oklahoma Heart Institute as additional U.S. sites.
- Imricor began construction on two ICMR labs in Saudi Arabia and supported an accredited ICMR summit in Riyadh in FY2025.
The players
Imricor Medical Systems
A medical device company that designs, manufactures, sells, and distributes magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures.
Steve Wedan
Chief Executive Officer of Imricor Medical Systems.
Jon
Chief Financial Officer of Imricor Medical Systems.
What they’re saying
“We must not let individuals continue to damage private property in San Francisco.”
— Robert Jenkins, San Francisco resident (San Francisco Chronicle)
“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”
— Gordon Edgar, grocery employee (Instagram)
The takeaway
Imricor's progress in regulatory approvals, clinical trials, and commercial infrastructure build positions the company to potentially drive broader adoption of its innovative MRI-guided cardiac ablation technology, which could improve outcomes and efficiency compared to traditional X-ray-guided procedures.
